×

TESARO Announces Five Abstracts to be Presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of five abstracts at the 2016 American Society of Clinical Oncology (ASCO) annual meeting, June 3 to June 7, 2016, in Chicago. In addition, TESARO will host an investor and analyst briefing in Chicago on Saturday, June 4 at 6:15 PM local time in conjunction with the ASCO annual meeting.

“Delayed chemotherapy-induced nausea and vomiting can be a debilitating side effect of chemotherapy. Because symptoms occur outside the clinic, patients don’t always report their experiences with delayed CINV. The two post-hoc analyses to be presented highlight increased control of CINV for patients who received VARUBI while being treated with chemotherapy for gynecologic and breast cancers,” said Mary Lynne Hedley, Ph.D., President and COO, TESARO. “In addition, posters describing currently ongoing studies, including a Phase 1 trial of niraparib plus bevacizumab in patients with ovarian cancer (AVANOVA), a Phase 1 trial of niraparib plus pembrolizumab in patients with triple-negative or recurrent ovarian cancer (KEYNOTE-162) and a Phase 3 trial of niraparib as a maintenance therapy in patients who have responded to first-line, platinum-based chemotherapy (PRIMA) will be presented.”

Please visit TESARO at Booth #14159 for information about VARUBI and our pipeline. TESARO will also be providing information on homologous recombination deficiency (HRD) and ovarian cancer at Booth #21047.

Presentation Details:

(VARUBI®) Rolapitant

Monday, June 6, 2016, 1:00 PM to 4:30 PM
Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer.
Abstract: 10121, Poster Board: 109, Location: S Hall A

Monday, June 6, 2016, 1:00 PM to 4:30 PM
Rolapitant for control of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer.
Abstract: 10122, Poster Board: 110, Location: S Hall A

Niraparib

Monday, June 6, 2016, 1:00 PM to 4:30 PM
A phase 1 study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: The ENGOT-OV24/AVANOVA1 trial.
Abstract #5555, Poster Board #378, Location: S Hall A

Monday, June 6, 2016, 1:00 PM to 4:30 PM
Phase 1/2 study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162).
Abstract #TPS5599, Poster Board #421a, Location: S Hall A

Monday, June 6, 2016, 1:00 PM to 4:30 PM
A randomized, double-blind phase 3 trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy.
Abstract #TPS5606, Poster Board #424b, Location: S Hall A

Niraparib is an investigational product candidate that has not been approved by any regulatory agencies.

Investor Briefing and Webcast
TESARO will host an investor and analyst briefing in Chicago on Saturday, June 4 at 6:15 PM local time in conjunction with the ASCO annual meeting. At this briefing, TESARO management will provide a business overview and pipeline update and will answer questions from investors and analysts. This event will be webcast live and archived for 30 days, and may be accessed from the TESARO Investor Events and Presentations webpage at www.tesarobio.com.

About VARUBI® (Rolapitant)
VARUBI is a substance P/neurokinin-1 (NK-1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. VARUBI is contraindicated in patients receiving thioridazine, a CYP2D6 substrate. The inhibitory effect of a single dose of VARUBI on CYP2D6 lasts at least seven days and may last longer. Avoid use of pimozide; monitor for adverse events if concomitant use with other CYP2D6 substrates with a narrow therapeutic index cannot be avoided. Please see full prescribing information, including additional important safety information, available at www.varubirx.com.

An intravenous formulation of rolapitant is also being developed. TESARO licensed exclusive rights for the development, manufacture, commercialization, and distribution of VARUBI (rolapitant) from OPKO Health, Inc.

About TESARO
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.

Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or jdavis@tesarobio.com

Source:TESARO, Inc.

More From Press Releases